Re: Farmas USA
AMRN
Lecroy mantiene PO 9 y confianza en adcom positivo
"We continue to think the panel will be positive because most panel outcomes are more positive than the FDA documents, and while studies have generally failed to show a statistical benefit of CV lowering, no trials have shown statistical harm and most show a numerical benefit of TG lowering or HDL raising. Additionally, Vascepa treatment has been extremely safe so there seems to be little concern that Vascepa use will cause harm to patients with high triglyceride (TG) levels."
«Después de nada, o después de todo/ supe que todo no era más que nada.»